{"id":548,"date":"2022-10-09T15:20:01","date_gmt":"2022-10-09T13:20:01","guid":{"rendered":"https:\/\/modafinil.pl\/sklep\/mebicar-mebicar-temgicoluril-30x-capsules-100mg-purity-%e2%89%a5-99\/"},"modified":"2026-10-03T06:11:58","modified_gmt":"2026-10-03T04:11:58","slug":"mebicar-2","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/mebicar-2\/","title":{"rendered":"Mebicar \/ Temgicoluril (CAS 10095-06-4) \u2014 laboratory reagent 1000 mg, purity \u2265 99%"},"content":{"rendered":"

1,3,4,6-tetramethyl-3a,6a-dihydroimidazo[4,5-d]imidazole-2,5-dione<\/strong> (common name: mebicar), crystalline powder, 1000 mg pack. Material intended exclusively for laboratory and analytical in vitro research<\/strong>. This product is not intended for human or animal consumption<\/strong>; it is not a medicinal product, food supplement, foodstuff or cosmetic.<\/p>\n

Three different entities that must not be confused<\/h2>\n

For this molecule, separating the layers is particularly important, because the same chemical name appears in the clinical literature under the trade name of a pharmaceutical preparation. Three contexts, three entirely different statuses:<\/p>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 medicinal product \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nWhat it concerns<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
mebicar, CAS 10095-06-4<\/th>\n		A chemical concept \u2014 a molecule of defined structure. In itself it is neither a medicine nor a reagent; its status is conferred only by the form in which it has been manufactured and authorised.<\/td>\nchemistry, substance registries<\/td>\n<\/tr>\n
Medicinal product
Adaptol, tablet form (Olainfarm JSC, Latvia)<\/th>\n		A pharmaceutical preparation manufactured under a pharmaceutical regime, present in the clinical literature under its trade name since at least 2009 [10<\/a>], used mainly in Russia and some CIS countries.<\/td>\nthe human clinical studies cited below concern this entity<\/strong><\/td>\n<\/tr>\n
Chemical reagent
material offered here<\/th>\n		Material for laboratory and analytical work. It does not have, and cannot have, authorisation for use in humans or animals<\/strong> \u2014 it has no pharmaceutical form or medicinal-product documentation.<\/td>\nanalytics, chemistry, reference standards<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> The study results cited further on this page were obtained either using the registered medicinal product<\/strong> (clinical studies involving humans) or using the substance administered to laboratory animals under controlled experimental conditions<\/strong> (preclinical studies). None of these studies was conducted using the analytical reagent<\/strong>, and none of their results transfers to the material offered. The reagent is not a form in which the substance has ever been studied in humans, and it cannot be used in such a way.<\/p>\n

Reagent identification sheet<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 mebicar<\/caption>\n
Systematic name (IUPAC)<\/th>\n1,3,4,6-tetramethyl-3a,6a-dihydroimidazo[4,5-d]imidazole-2,5-dione<\/td>\n<\/tr>\n
Common names<\/th>\nmebicar, mebikar<\/td>\n<\/tr>\n
Chemical class name<\/th>\ntetramethylglycoluril (Temgicoluril)<\/td>\n<\/tr>\n
CAS number<\/th>\n10095-06-4<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC8<\/sub>H14<\/sub>N4<\/sub>O2<\/sub><\/td>\n<\/tr>\n
Molar mass<\/th>\n198.22 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n198.1117 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nXIUUSFJTJXFNGH-UHFFFAOYSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nCN1C2C(N(C1=O)C)N(C(=O)N2C)C<\/td>\n<\/tr>\n
PubChem CID<\/th>\n122282<\/a><\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL4303164<\/a> \u2014 status: preclinical (max_phase 0)<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder, white to off-white<\/td>\n<\/tr>\n
Purity<\/th>\n\u2265 99%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for human or animal consumption<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lineage of the molecule: a bicyclic bis-urea of the glycoluril family<\/h2>\n

The first PubMed-indexed paper on this molecule dates from 1977 and describes it directly as a derivative of bicyclic bis-ureas<\/strong> (bicyclic bis-ureas<\/em>), placing the then-new compound between the classical tranquillisers and the neuroleptics [1<\/a>]. Five years later the same team refined the structural classification as a derivative of tetra-N-alkylated bicyclic bis-ureas<\/strong> [3<\/a>] \u2014 a term that corresponds exactly to the core known in organic chemistry as glycoluril<\/strong>: two imidazolidine rings fused along an edge, each terminating in a urea (carbonyl) group.<\/p>\n

From glycoluril to mebicar: full methyl substitution<\/h3>\n

Glycoluril itself (unsubstituted) has been known since the end of the 19th century and today remains primarily a building block in supramolecular chemistry \u2014 it is used to synthesise cucurbituril macrocycles, employed as molecular hosts. Mebicar is formed by substituting all four nitrogen atoms with methyl groups<\/strong> (hence the synonym \u201ctetramethylglycoluril\u201d). This seemingly minor modification has a serious structural consequence, described below in the chemistry section: it abolishes the molecule\u2019s ability to act as a hydrogen bond donor.<\/p>\n

The first decade of research (1977\u20131990)<\/h3>\n

The early papers, published almost exclusively in Russian and indexed under translated titles, built up the pharmacological profile of the compound through successive animal studies: effects on the orienting response and seizure threshold [1<\/a>], elimination of the fear response in cats without accompanying muscle-relaxant or hypnotic action, and effects on brain noradrenaline and serotonin levels [2<\/a>], a GABA-ergic component of action [3<\/a>] and cardiovascular responses [6<\/a>]. In parallel, the first clinical pharmacokinetic studies were conducted [4<\/a>].<\/p>\n

Timeline<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Timeline: from the first publication to contemporary clinical studies<\/caption>\n
1977<\/th>\nfirst PubMed-indexed pharmacological publication, classifying the compound as a derivative of bicyclic bis-ureas [1<\/a>]<\/td>\n<\/tr>\n
1980\u20131990<\/th>\na series of Soviet preclinical studies building the pharmacological, toxicological and cardiological profile [2<\/a>][3<\/a>][5<\/a>][6<\/a>]<\/td>\n<\/tr>\n
1984<\/th>\nclinical pharmacokinetic study in patients of an addiction clinic \u2014 correlation of pharmacodynamic and pharmacokinetic parameters [4<\/a>]<\/td>\n<\/tr>\n
1996<\/th>\ncontinuation of preclinical research: effect on lipid metabolism in a rat hypokinesia model [7<\/a>]<\/td>\n<\/tr>\n
2009<\/th>\nfirst indexed paper using the trade name of the pharmaceutical preparation (see the table \u00abThree different entities\u00bb above) in a clinical context \u2014 treatment of ADHD [10<\/a>]<\/td>\n<\/tr>\n
2011<\/th>\ncomparative studies with classical medicines (amitriptyline, diazepam) in animal models [8<\/a>]; clinical study of cervicogenic headache [11<\/a>]<\/td>\n<\/tr>\n
2012\u20132016<\/th>\na series of clinical studies on the use of the pharmaceutical preparation listed in the table \u00abThree different entities\u00bb in anxiety disorders of various origins, including a randomised study in chronic cerebral ischaemia [12<\/a>][13<\/a>]<\/td>\n<\/tr>\n
2020<\/th>\ncomparative study of mebicar and mianserin in patients with psoriasis and co-existing anxiety [14<\/a>]<\/td>\n<\/tr>\n
2023\u20132024<\/th>\nthe most recent clinical papers: combined treatment in hypertension and post-COVID syndrome in older people [15<\/a>] and a randomised study of anxiety therapy supported by a mobile application [16<\/a>]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research centres and groups that built the literature<\/h2>\n

As with other molecules of Soviet lineage, the literature on mebicar has a clear geography and divides into several distinct periods and teams:<\/p>\n